BPH
Conditions
Brief summary
This prospective, multicenter, two-arm, 1:1 randomized controlled trial (RCT) will enroll approximately 250 males at approximately 25 sites located within the United States. All enrolled subjects will be 45 years of age or older diagnosed with symptomatic benign prostatic hyperplasia (BPH). They will be randomized to one of two readily available, marketed BPH therapies; Prostatic Urethral Lift procedure with the UroLift System (PUL Arm) or 0.4mg tamsulosin HCl (MED Arm).
Detailed description
This prospective, multicenter, two-arm, 1:1 randomized controlled trial (RCT) will enroll approximately 250 males at approximately 25 sites located within the United States. All enrolled subjects will be 45 years of age or older diagnosed with symptomatic benign prostatic hyperplasia (BPH). They will be randomized to one of two readily available, marketed BPH therapies; Prostatic Urethral Lift procedure with the UroLift System (PUL Arm) or 0.4mg tamsulosin HCl (MED Arm).Men 45 or older diagnosed with symptomatic benign prostatic hyperplasia (BPH). BPH symptoms may range from mild (8) to severe (35) on the IPSS scale. All enrolled men must meet selection criteria and be candidates for therapy with both UroLift System and 0.4 mg tamsulosin HCl.
Interventions
DEVICEUroLift System
Prostatic lift
Tamsulosin HCl 0.4mg
Sponsors
NeoTract, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
45 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Male 45 years of age or older 2. Diagnosis of BPH 3. Experiencing symptoms of BPH as indicated by an IPSS ≥8 and ≤30 4. Willing to wash out of current BPH medication(s), as applicable 5. An appropriate candidate for both BPH therapies evaluated in this study. 6. Ability to understand and consent to participate in this study 7. Willing and able to participate in follow-up evaluations
Exclusion criteria
1. Use of alpha blocker for BPH unless washed-out for 30 days 2. Use of daily phosphodiesterase type 5 inhibitor (PDE5i) for BPH unless washed-out for 30 days 3. 5-alpha-reductase inhibitors for BPH used within 6 months of therapy initiation 4. Current urinary tract infection or prostatitis 5. Current gross hematuria 6. Urinary incontinence presumed due to incompetent sphincter 7. Catheter-dependent urinary retention within 1 month prior to enrollment 8. Prostate volume greater than 100 cc as measured by TRUS 9. Prostate specific antigen level of greater than 10 ng/ml within one year of enrollment unless prostate cancer has been ruled out 10. History of neurogenic or atonic bladder 11. History prostate cancer treatment 12. Known to be hypersensitive to tamsulosin HCl or any component of tamsulosin HCl capsules 13. Known allergy to nickel, titanium, or stainless steel 14. Prior minimally invasive or surgical intervention for BPH 15. Urethral conditions that may prevent insertion of delivery system into bladder. 16. Currently enrolled in any other investigational clinical research trial that has not completed the primary endpoint 17. History of medical, surgical or other conditions that, in the opinion of the investigator, would interfere with the treatment or evaluation of the subject
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Paired comparison of International Prostate Symptom Score (IPSS) percent change | 3 Months after Therapy Initiation | The primary study analysis compares the change in BPH symptoms in the PUL Arm to the change in BPH symptoms in the MED Arm measured 3 months after BPH therapy initiation. This will be measure by International Prostate Symptom Score (IPSS) percent change. IPSS ranges from 0-35, healthier patients have lower scores than patients more effected by BPH symptoms. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Quality of Life (QoL) | 3 months after BPH Therapy Initiation | The secondary analysis assesses the change in quality of life (QoL) due to urinary symptoms between the PUL and MED Arms measured 3 months after initiation of BPH therapy. This will be measured by change in QoL, ranging from 0-6. Healthier patients have lower scores than patients more effected by BPH symptoms. |
Countries
United States
Contacts
Primary ContactRogers Mitchell
Outcome results
None listed